Current Report Filing (8-k)
July 14 2016 - 9:47AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported) July 14, 2016 (July 8, 2016)
MEDIFIRST SOLUTIONS, INC
(Exact name of registrant as specified
in its charter)
Nevada
|
|
000-55465
|
|
27-3888260
|
(State or other
|
|
(Commission File Number)
|
|
(IRS Employer
|
jurisdiction incorporation)
|
|
|
|
Identification No.)
|
|
|
|
|
|
4400 Route 9 South, Suite 1000, Freehold, NJ
|
|
07728
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including
area code: (732)-786-8044
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation
FD Disclosure
On July 8, 2016,
Medifirst Solutions, Inc. (the “Company”), in response to its Premarket Notification 510(k) submission for “The
Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its
infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. Given the FDA clearance the Company intends to update shareholder
on its operational strategies on or around July 22, 2016.
The information
in this Item 7.01 disclosure, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that
Section. In addition, the information in this Item 7.01 disclosure, including Exhibits 99.1, shall not be incorporated by reference
into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
hereunto duly authorized.
|
MEDIFIRST SOLUTIONS, INC.
|
|
|
Dated: July 14, 2016
|
By:
|
/s/ Bruce Schoengood
|
|
|
Bruce Schoengood
President and Chief Executive Officer
|